GlassScriptPhysician profile
Aminder Mehdi
NPI 1780612507
$11,084.82
in general payments reported to CMS, 2019-2025
78 companies · $2,540 in 2025
The $2,540 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,289 · 2020: $1,213 · 2021: $1,193 · 2022: $1,158 · 2023: $1,197 · 2024: $1,495 · 2025: $2,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,520 · Long Term Medical Supply Or Device Loan: $1,347 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,519.82 |
| Long Term Medical Supply Or Device Loan | $1,346.69 |
| Education | $365.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,252.19 | 2019-2025 | |
| Janssen Biotech, INC. | $781.77 | 2019-2025 | Rybrevant, Akeega, Erleada |
| E.R. Squibb & Sons, L.L.C. | $488.48 | 2019-2025 | Opdivo |
| Pfizer INC. | $470.74 | 2019-2025 | |
| Seagen INC. | $305.37 | 2019-2023 | Tivdak |
| Genentech USA, INC. | $298.03 | 2019-2025 | Polivy, Itovebi, Venclexta |
| Celgene Corporation | $292.66 | 2019-2025 | Reblozyl |
| Abbvie INC. | $273.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $256.58 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Astellas Pharma US INC | $248.49 | 2019-2025 | Vyloy, Cresemba |
| Regeneron Healthcare Solutions, INC. | $242.41 | 2021-2025 | Libtayo, Lynozyfic |
| Genzyme Corporation | $233.29 | 2019-2025 | |
| Gilead Sciences, INC. | $232.82 | 2019-2025 | Trodelvy |
| Incyte Corporation | $209.28 | 2019-2025 | Jakafi, Jakafi |
| Beigene USA, INC. | $205.57 | 2022-2024 | Brukinsa |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aminder Mehdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.